New Horizons in the Treatment and Management of Hepatocellular Carcinoma (HCC): Expert Perspectives on the Evolving Role of Immunotherapy

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2020 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from November 1, 2020 to March 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.

Description:
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and the prevalence and mortality rate of liver cancer has been rising steadily over the past decade. Liver cancer is still on the rise and death rates are increasing faster than any other type of cancer. Fortunately for patients with HCC, new agents have become available in the past few years, including novel immunotherapies. They have shown the ability to improve safety and efficacy outcomes, especially with dual immune checkpoint blockade in the 1st-line advanced HCC setting. Several immunotherapies are currently undergoing late stage clinical trials or regulatory review as well in advanced HCC. For the treatment of HCC, transplantation is an option for patients. Unfortunately, there is a limited supply of good-quality deceased donor organs. Thus, other treatments, including systemic therapy, should be used to bridge patients to transplant or to delay recurrence if possible, in HCC. Fortunately, clinicians have been equipped with new individualized options in the past few years, including immunotherapies, which provide options for the unmet need of treatment in HCC, especially in dual immune checkpoint blockade in the 1st-line advanced HCC setting. Several PD-L1 immunotherapy options are currently undergoing late stage clinical trials or regulatory review that have shown the ability to continue to close gaps in treatment for patients with advanced HCC. Immune checkpoint inhibitors have shown improved efficacy and safety in HCC, and healthcare professionals must be educated on these options, how they should be integrated into the treatment paradigm, and the potential risks that come along with any treatment option.

Upon completion of this activity, participants will be able to:

  • Examine the biologic rationale for integrating immunotherapy into the treatment armamentarium for HCC

  • Analyze recent clinical trial data surrounding new and emerging immunotherapies, including dual immunotherapy combinations, in HCC for informed decision-making

  • Identify patients with advanced HCC for whom immunotherapies, including dual immune checkpoint blockade, is an appropriate choice for the next step in the management of their cancer, especially in the 1st-line advanced HCC setting

  • Compare and contrast the mechanisms of action, safety and efficacy of new and emerging immunotherapies, and their combinations, in the treatment of HCC

  • Discuss strategies for anticipating, recognizing, and managing adverse events of immunotherapies in HCC

  • Assess the managed care considerations of dual immune checkpoint blockade combinations by exploring where these agents fit into current advanced HCC management paradigm

     

Faculty: Richard S. Finn, MD
Professor of Medicine
Geffen School of Medicine, Division of Hematology/Oncology
University of California Los Angeles

Disclosure:

Dr. Finn serves as a consultant for AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Eli Lilly, Cstone, Roche/Genentech, Merck, and Pfizer. He has received grant/research support from Eisai, Eli Lilly, Merck, Pfizer, and Roche/Genentech. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue